|
|
多囊卵巢综合征患者血清25-羟维生素D水平对代谢综合征的初筛价值
|
Abstract:
目的：分析多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者血清25-羟维生素D水平与代谢综合征(metabolic syndrome, MS)的相关性及对MS的初筛价值。方法：连续纳入2023年9月至2024年9月于重庆医科大学附属第二医院妇科就诊，符合入组标准的PCOS患者161例，按照血清25-羟维生素D水平分为严重缺乏组(n = 40)、缺乏组(n = 96)和不缺乏组(n = 25)，收集所有患者的临床资料，比较三组患者的腰围、血清甘油三酯及高密度脂蛋白胆固醇水平等MS相关指标。应用Logistic回归模型分析血清25-羟维生素D水平与MS的相关性。以漏诊率 < 10%确定血清25-羟维生素D在PCOS患者中筛查MS的截断值，并采用混淆矩阵评价其筛查效能。结果：血清25-羟维生素D严重缺乏组的MS患病率(75.0%)显著高于缺乏组(15.6%)和不缺乏组(0.0%)，差异有统计学意义(P = 0.000)。血清25-羟维生素D (OR = 0.006, 95% CI 0.001~0.045, P = 0.000)及血清黄体生成素(OR = 0.231, 95% CI 0.084~0.635, P = 0.004)是PCOS患者发生MS的保护因素，体质量指数(OR = 3.619, 95% CI 1.433~9.141, P = 0.007)是PCOS患者发生MS的危险因素。在PCOS患者中应用血清25-羟维生素D (<32.25 nmol/L)初筛MS的召回率为91.11%，准确率为73.91%。结论：低血清25-羟维生素D水平可能增加PCOS患者合并MS的风险，血清25-羟维生素D对MS具有良好的初筛价值。
Objective: To analyze the correlation between serum 25-hydroxyvitamin D level and metabolic syndrome (MS) in patients with polycystic ovary syndrome (PCOS) and its screening value for MS. Methods: A total of 161 patients with PCOS who met the inclusion criteria and were admitted to the Second Affiliated Hospital of Chongqing Medical University from September 2023 to September 2024 were enrolled. According to the degree of serum 25-hydroxyvitamin D deficiency, they were divided into severe deficiency group (n = 40), deficiency group (n = 96) and non-deficiency group (n = 25). Clinical data of all patients were collected and waist circumference, triglyceride and high density lipoprotein cholesterol were compared among the three groups. Logistic regression model was established to analyze the correlation between serum 25-hydroxyvitamin D level and MS. A missed diagnosis rate of <10% was used to determine the cut-off value of serum 25-hydroxyvitamin D for MS screening in patients with PCOS. Confounding matrix evaluation of screening efficacy of serum 25-hydroxyvitamin D for PCOS with MS. Results: Prevalence of MS in severe serum 25-hydroxyvitamin D deficiency group (75.0%) significantly higher than the deficiency group (15.6%) and non-deficiency group (0.0%), statistically significant difference(P = 0.000); Serum 25-hydroxyvitamin D (OR = 0.006, 95% CI 0.001~0.045, P = 0.000) and serum luteinizing hormone (OR = 0.231, 95% CI 0.084~0.635, P = 0.004) was a protective factor for MS in PCOS patients, body mass index(OR = 3.619, 95% CI 1.433~9.141, P = 0.007) was a risk factor for MS in PCOS patients. The recall rate and accuracy rate of MS screening in PCOS patients using serum 25-hydroxyvitamin D cut-off value of 32.25 nmol/L were
| [1] | Yang, R., Li, Q., Zhou, Z., Qian, W., Zhang, J., Wu, Z., et al. (2022) Changes in the Prevalence of Polycystic Ovary Syndrome in China over the Past Decade. The Lancet Regional Health—Western Pacific, 25, Article ID: 100494. https://doi.org/10.1016/j.lanwpc.2022.100494 |
| [2] | Glintborg, D., Rubin, K.H., Nybo, M., Abrahamsen, B. and Andersen, M. (2018) Cardiovascular Disease in a Nationwide Population of Danish Women with Polycystic Ovary Syndrome. Cardiovascular Diabetology, 17, Article No. 37. https://doi.org/10.1186/s12933-018-0680-5 |
| [3] | Chen, W. and Pang, Y. (2021) Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites, 11, Article 869. https://doi.org/10.3390/metabo11120869 |
| [4] | 中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会, 倪青. 代谢综合征病证结合诊疗指南[J]. 世界中医药, 2023, 18(22): 3157-3166. |
| [5] | Benjamin, E.J., et al. (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 135, e146-e603. |
| [6] | Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645. https://doi.org/10.1161/circulationaha.109.192644 |
| [7] | 中国医师协会内分泌代谢科医师分会. 多囊卵巢综合征诊治内分泌专家共识[J]. 中华内分泌代谢杂志, 2018, 34(1): 1-7. |
| [8] | 王红梅, 王芳. 维生素D与多囊卵巢综合征相关性研究进展[J]. 中国生育健康杂志, 2019, 30(3): 291-293. |
| [9] | Lee, S.J., Lee, E.Y., Lee, J.H., Kim, J.E., Kim, K.J., Rhee, Y., et al. (2019) Associations of Serum 25-Hydroxyvitamin D with Metabolic Syndrome and Its Components in Elderly Men and Women: The Korean Urban Rural Elderly Cohort Study. BMC Geriatrics, 19, Article No. 102. https://doi.org/10.1186/s12877-019-1118-y |
| [10] | Gagnon, C., Lu, Z.X., Magliano, D.J., Dunstan, D.W., Shaw, J.E., Zimmet, P.Z., et al. (2012) Low Serum 25-Hydroxyvitamin D Is Associated with Increased Risk of the Development of the Metabolic Syndrome at Five Years: Results from a National, Population-Based Prospective Study (the Australian Diabetes, Obesity and Lifestyle Study: Ausdiab). The Journal of Clinical Endocrinology & Metabolism, 97, 1953-1961. https://doi.org/10.1210/jc.2011-3187 |
| [11] | Asemi, Z., Foroozanfard, F., Hashemi, T., Bahmani, F., Jamilian, M. and Esmaillzadeh, A. (2015) Calcium Plus Vitamin D Supplementation Affects Glucose Metabolism and Lipid Concentrations in Overweight and Obese Vitamin D Deficient Women with Polycystic Ovary Syndrome. Clinical Nutrition, 34, 586-592. https://doi.org/10.1016/j.clnu.2014.09.015 |
| [12] | Eshre, T.R. and ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. Fertility and Sterility, 81, 19-25. |
| [13] | 中华医学会骨质疏松和骨矿盐疾病分会. 维生素D及其类似物临床应用共识[J]. 协和医学杂志, 2018, 9(2): 127-143. |
| [14] | Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C. and Muñoz-Torres, M. (2021) Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. Nutrients, 13, Article 3491. https://doi.org/10.3390/nu13103491 |
| [15] | Chun, R.F., Liu, P.T., Modlin, R.L., Adams, J.S. and Hewison, M. (2014) Impact of Vitamin D on Immune Function: Lessons Learned from Genome-Wide Analysis. Frontiers in Physiology, 5, Article 151. https://doi.org/10.3389/fphys.2014.00151 |
| [16] | 汤娟, 王若光. 多囊卵巢综合征的病因病理[J]. 中国现代医生, 2014, 52(4): 151-153. |
| [17] | Thomson, R.L., Spedding, S. and Buckley, J.D. (2012) Vitamin d in the Aetiology and Management of Polycystic Ovary Syndrome. Clinical Endocrinology, 77, 343-350. https://doi.org/10.1111/j.1365-2265.2012.04434.x |
| [18] | Guo, S., Tal, R., Jiang, H., Yuan, T. and Liu, Y. (2020) Vitamin D Supplementation Ameliorates Metabolic Dysfunction in Patients with PCOS: A Systematicreview of RCTs and Insight into the Underlying Mechanism. International Journal of Endocrinology, 2020, Article ID: 7850816. https://doi.org/10.1155/2020/7850816 |
| [19] | Hahn, S., Haselhorst, U., Tan, S., Quadbeck, B., Schmidt, M., Roesler, S., et al. (2006) Low Serum 25-Hydroxyvitamin D Concentrations Are Associated with Insulin Resistance and Obesity in Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology & Diabetes, 114, 577-583. https://doi.org/10.1055/s-2006-948308 |
| [20] | Del Pinto, R., Wright, J.T., Monaco, A., Pietropaoli, D. and Ferri, C. (2020) Vitamin D and Blood Pressure Control among Hypertensive Adults: Results from NHANES 2001-2014. Journal of Hypertension, 38, 150-158. https://doi.org/10.1097/hjh.0000000000002231 |
| [21] | 李信昱, 杨宁. 血压的季节性变化研究进展[J]. 中华高血压杂志, 2022, 30(9): 826-829. |
| [22] | Zhang, Y., Kong, J., Deb, D.K., Chang, A. and Li, Y.C. (2010) Vitamin D Receptor Attenuates Renal Fibrosis by Suppressing the Renin-Angiotensin System. Journal of the American Society of Nephrology, 21, 966-973. https://doi.org/10.1681/asn.2009080872 |
